AMW Appoints Additional Experts for Drug Delivery Systems to its Scientific Advisory Board

Warngau, Germany, July 1, 2024

AMW GmbH, a specialty bio-pharmaceutical company focused on innovative sustained-release drug delivery systems, today announced the appointment of Prof. Miriam Breunig, Senior Academic Councillor at the University of Regensburg’s Department of Pharmaceutical Technology, and Prof. Karsten Mäder, Professor of Pharmaceutics at Martin Luther University Halle-Wittenberg, as members to AMW’s Scientific Advisory Board. Following the departure of long-standing members Dr. Dirk Schrader and Dr. Georg Ingram, the Board once again consists of three members with Prof. Olivia Merkel, who has been a member of the Scientific Advisory Board since the beginning of 2023.

“We are delighted to welcome Prof. Breunig and Prof. Mäder to our Scientific Advisory Board,” said Philipp Karbach, CEO of AMW. “At the same time, we would like to express our sincere thanks to Dr. Schrader and Dr. Ingram for their many years of support for AMW. The development that our company has undergone in recent years has been made possible not least by their support and professional expertise. Our high-profiled Scientific Advisory Board will continue to support us in the future on scientific topics and strategic matters and will accompany AMW’s growth path with a focus on biodegradable drug delivery systems.”

“It is a tremendous advantage for AMW to benefit from Scientific Advisory Board members with such extensive R&D expertise,” added Dr. Eric Wittchow, Vice President R&D of AMW. “Our focus on research and development of innovative drug delivery systems will be further strengthened by the intensive exchange with our Scientific Advisory Board, and I am very much looking forward to our future collaboration.”

Prof. Breunig’s work at University of Regensburg’s Department of Pharmaceutical Technology focuses on developing innovative drug delivery systems for small molecules and biologics like proteins and nucleic acids, which significantly enhances patient-centric therapies. In addition, her work has been instrumental in understanding the interaction between nanoparticulate materials and biological tissues to improve the design of drug delivery systems.

Prof. Mäder is specialized in biodegradable polymers and drug delivery systems. His research at Martin Luther University Halle-Wittenberg concentrates on nano-drug delivery systems, its noninvasive characterization, parenteral controlled release forms, and enhancing oral bioavailability. In very close cooperation with clinicians he develops new drug delivery systems for the treatment of dental diseases, the eye and the inner ear.

Further information on the members of AMW’s Scientific Advisory Board can be found on our website at


About AMW:

AMW GmbH is a specialty bio-pharmaceutical company focused on biodegradable sustained-release drug delivery systems, providing patients and partners access to value-added medicines and cost-effective therapies. Based on its technology platform, the Company builds on a growing own and partnered development pipeline. AMW has two approved products, goserelin and leuprorelin implants, which are distributed worldwide through both local and global pharma partners. In Germany, leuprorelin is marketed as Leugon® by AMW’s wholly owned subsidiary Endomedica GmbH. To support pharma and biotech partners in the development and manufacturing of their products and life-cycle solutions, AMW uses its leading-edge formulation development expertise.

AMW is based in Warngau near Munich, Germany.

For further information please contact:

Eva Hoffmann
Phone: +49 8024 470999-0 E-mail: